Expression of versican mRNA transcript to predict cardiac remodelling after myocardial infarction

Kardiol Pol. 2021;79(7-8):833-840. doi: 10.33963/KP.a2021.0042. Epub 2021 Jun 24.

Abstract

Background: Adverse left-ventricular remodelling (LVR) is defined as an increase in end-diastolic left-ventricular volume by 20% 6 months after acute myocardial infarction (AMI). LVR is associated with cardiac dysfunction, therefore deteriorating the prognosis.

Aims: We aimed to compare the concentrations of messenger RNA transcripts in the peripheral blood of patients with and without LVR at 6 months.

Methods: The study included 75 patients with first ST-elevation myocardial infarction (STEMI) treated with percutaneous coronary intervention. Whole blood concentrations of 6 transcripts were determined 24 hours after AMI using droplet digital polymerase chain reaction. The correlations between mRNA transcript expression and left ventricular ejection fraction (LVEF) and N-terminal-pro B type natriuretic peptide (NT-proBNP) concentration were evaluated.

Results: Among 75 patients, 4 were lost to follow-up and 71 were included in the analysis. Seventeen (24%) patients developed LVR at 6 months. Versican (VCAN) mRNA expression was lower in patients who developed LVR, compared to those who did not (P = 0.02), and discriminated between these patients (area under the ROC curve 67%; P = 0.04). Expression of VCAN transcript < 75.3 normalized units predicted LVR with 71% sensitivity and 67% specificity. In a multivariable regression analysis, VCAN expression remained the only independent predictor of LVR (OR 3.475; 95% CI, 1.000-12.075; P = 0.04).

Conclusions: Dysregulation of VCAN expression in the acute phase of AMI may contribute to LVR at 6 months. Whether decreased expression of VCAN might be a useful tool to predict LVR in clinical practice remains to be established.

Keywords: cardiac remodeling; mRNA transcripts; myocardial infarction; versican.

MeSH terms

  • Biomarkers
  • Humans
  • Myocardial Infarction*
  • Prognosis
  • RNA, Messenger / genetics
  • ST Elevation Myocardial Infarction* / surgery
  • Stroke Volume
  • Ventricular Function, Left
  • Ventricular Remodeling
  • Versicans / genetics

Substances

  • Biomarkers
  • RNA, Messenger
  • Versicans